期刊文献+

液相色谱串接质谱联用法分析人体志愿者尿样中克仑特罗 被引量:5

Determination of Clenbuterol in Human Urine by High Pressure Liquid Chromatography-tandem Mass Spectrometry
下载PDF
导出
摘要 目的:建立液相色谱串接质谱联用法检测人体志愿者尿样中克仑特罗检测方法。方法:尿样经过液液萃取提取,以10 mmol/L p H3.5甲酸铵和乙腈为流动相,采用Agilent Eclipse PLUS C18150 mm×4.6mm×3.5μm色谱柱分离,电喷雾离子源,正离子多反应监测模式扫描分析检测,D9-克仑特罗为内标。采用该方法分析了4名人体志愿者尿样中的克仑特罗。结果:该方法的检测限为0.02μg/L,定量限为0.04μg/L,在添加的高、中、低三种浓度的相对回收率分布在85%~100%之间。结论:分析了克仑特罗在人体尿液中代谢规律。方法满足常规检测要求,样品前处理简单、快速、可靠。 Objective To develop a method for determination of clenbuterol in human urine. Methods The urines from 4 volunteers were prepared by liquid-liquid phase extraction. Clenbuterol in urine was separated by Agilent Eclipse PLUS C18 (150 mm×4.6mm×3.5μm) column and detected by HPLC-MS/MS using D9- clenbuterol as internal standard,and ammonium formate and methyl cyanides as mobile phase. Results The detectability of the method was 0.02μg/L,and limit of quantitation was 0.04 μg/L. The relative recovery of target compounds ranged from 85 to 100% respectively at high- ,moderate- ,and low concentrations. Conclusion The method introduced in this study is simple, rapid, reliable, and suitable for routine analysis in human urine.
出处 《中国运动医学杂志》 CAS 北大核心 2015年第3期309-312,共4页 Chinese Journal of Sports Medicine
关键词 克仑特罗 兴奋剂 尿样 液相色谱串接质谱联用法(HPLC-MS/MS) clenbuterol, doping, human urine, HPLC-MS/MS
  • 相关文献

参考文献8

二级参考文献50

共引文献49

同被引文献52

  • 1叶培,岳振峰,肖陈贵,赵凤娟,郑宗坤,沈金灿,韩瑞阳,林黎.液相色谱-串联质谱法检测猪肉中28种β_2-受体激动剂[J].食品安全质量检测学报,2013,4(3):682-688. 被引量:18
  • 2吴筠,崔凯荣,王杉,徐友宣,申利.用GC-MS法测定尿中可待因及其代谢物的浓度[J].分析测试学报,1994,13(3):71-74. 被引量:3
  • 3秦旸,徐友宣,吴侔天.液相色谱-质谱法快速筛选人尿中26种利尿剂[J].质谱学报,2007,28(4):229-232. 被引量:12
  • 4Schrier RW,Gross P,Gheorghiade M,et al.?Tolvaptan,a selective oral vasopressin V2-receptor antagonist,for hyponatremia.New England Journal of Medicine.2006,355(20):2099-2112.
  • 5Abraham WT,Shamshirsaz AA,Mcfann K,et al.Aquaretic effect of lixivaptan,an oral,non-peptide,selective V2 receptor vasopressin antagonist,in New York Heart Association functional class II and III chronic heart failure patients.J Am Coll Cardiol.2006,47(8):1615-1621.
  • 6Potts MB,Degiacomo AF,Deragopian L,et al.Use of intravenous conivaptan in neurosurgical patients with hyponatremia from syndrome of inappropriate antidiuretic hormone secretion.Neurosurgery.2011,69(2):268-273.
  • 7World Anti-Doping Agency:The 2014 Prohibited List.http://www.wada-ama.org.
  • 8Pei Q,Zhang BK,Tan HY,et al.Development and validation of an LC-MS/MS method for the determination of tolvaptan in huaman plasma and its application to a pharmacokitic study.J Chromatogr B,2013,913-914:84-89.
  • 9Derangula VR,Pillinr,Bhukya BR,et al.Bioanalysis of tolvaptan,a novel AVP-V2 receptor antagonist in human plasma by a novel LC-ESI-MS/MS method:a pharmacokinetic application in healthy south Indian male subject.Biomed Chromatogr,2014,28(3):332-340.
  • 10World Anti-Doping Agency:WADA Technical Document.http://www.wada-ama.org.

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部